Qiagen N.V. (QGEN)
$
45.28
-0.78 (-1.72%)
Key metrics
Financial statements
Free cash flow per share
2.2919
Market cap
9.8 Billion
Price to sales ratio
4.8065
Debt to equity
0.4119
Current ratio
1.6121
Income quality
1.8079
Average inventory
287 Million
ROE
0.1066
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
QIAGEN N.V. offers comprehensive sample to insight solutions that facilitate the transformation of biological materials into valuable molecular insights globally. The company provides a range of primary sample technology consumables, including nucleic acid stabilization and purification kits tailored for primary sample materials. It supports both manual and automated processing for various applications such as genotyping, gene expression analysis, and the study of viral and bacterial samples, utilizing advanced technologies like silica membranes and magnetic beads. Additionally, QIAGEN supplies secondary sample technology consumables that include kits and components for nucleic acid purification from secondary samples. The company's product offerings extend to instruments for nucleic acid purification, various accessories, and specialized assays including interferon-gamma release assays for TB testing, post-transplant testing assays, and viral load monitoring. QIAGEN also offers prenatal testing solutions, assays for detecting sexually transmitted diseases and HPV, as well as genomic variant analysis methods that identify mutations, insertions, deletions, and fusions. The sample to insight instruments feature one-step molecular analyses designed for complex syndromes and integrated PCR testing. The company provides a multitude of PCR consumables, including quantitative PCR and reverse transcription kits furthering analysis in areas like gene expression and regulation. Moreover, QIAGEN caters to human identification and forensics with STR assays, alongside food contamination testing. Its PCR instrument line includes innovative digital PCR solutions and tailored OEM consumables. Additionally, the company provides predefined and custom NGS gene panels, library preparation kits, and services for whole genome amplification, along with various bioinformatics solutions and custom laboratory services. Recently, the company reported selling, general, and administrative expenses of $564,361,000.00 indicating its operational overhead costs. Meanwhile, it recorded a net income of $83,591,000.00 which reflects its profitability. This performance is supported by an income before tax ratio of 0.06 demonstrating a solid pre-tax margin. The earnings per share (EPS) is reported at $0.39 highlighting the company's profitability on a per-share basis. Moreover, it recorded a substantial revenue of $1,978,214,000.00 underscoring its strong market presence. The stock is affordable at $45.28 making it an attractive option for budget-conscious investors. With an average trading volume of 1,444,669.00 the stock demonstrates moderate liquidity, appealing to a range of investors. Holding a mid-range market capitalization of $9,805,655,680.00 the company positions itself as a steady performer within the competitive landscape. QIAGEN is a key player in the Medical - Diagnostics & Research industry, significantly contributing to the overall market dynamics and advancements. It belongs to the Healthcare sector, where it drives innovation and fosters growth, reinforcing its role as a leader in molecular diagnostics and related fields.
Is Qiagen N.V. (QGEN) a good investment?
Investing in Qiagen N.V. (QGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Qiagen N.V. (QGEN)'s stock forecast?
Analysts predict Qiagen N.V. stock to fluctuate between $37.63 (low) and $51.88 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Qiagen N.V.'s market capitalization?
As of 2025-09-12, Qiagen N.V.'s market cap is $9,805,655,680, based on 216,556,000 outstanding shares.
How does Qiagen N.V. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Qiagen N.V. has a Lower Market-Cap, indicating a difference in performance.
Does Qiagen N.V. pay dividends?
Qiagen N.V. pays dividends. The current dividend yield is 2.88%, with a payout of $1.26 per share.
How can I buy Qiagen N.V. (QGEN) stock?
To buy Qiagen N.V. (QGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for QGEN. Place an order (Market, Limit, etc.).
What is the best time to invest in Qiagen N.V.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Qiagen N.V. stock ever split?
Qiagen N.V.'s last stock split was 35:36 on 2025-01-29.
How did Qiagen N.V. perform in the last earnings report?
Revenue: $1,978,214,000 | EPS: $0.39 | Growth: -74.68%.
Where can I find Qiagen N.V.'s investor relations reports?
Visit https://www.qiagen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Qiagen N.V.?
You can explore historical data from here
What is the all-time high and low for Qiagen N.V. stock?
All-time high: $61.50 (2021-11-26) | All-time low: $36.84 (2023-10-30).
What are the key trends affecting Qiagen N.V. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections. The QIAstat-Dx system now offers CE-IVDR certified panels for respiratory, gastrointestinal and CNS infections that help clinicians d.
seekingalpha.com
Qiagen N.V. (NYSE:QGEN ) Baird Global Healthcare Conference 2025 September 10, 2025 1:25 PM EDT Company Participants Roland Sackers - CFO, MD & Member of Management Board John Gilardi - VP & Head of Corporate Communications Presentation Unknown Analyst Diagnostics here at Baird.
seekingalpha.com
Qiagen N.V. (NYSE:QGEN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Roland Sackers - CFO, MD & Member of Management Board John Gilardi - VP & Head of Corporate Communications Conference Call Participants Aisyah Noor - Morgan Stanley, Research Division Presentation Aisyah Noor Equity Analyst So thanks for joining us today.
businesswire.com
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide. The new system, which received clearance from the U.S. Food and Drug Administration (FDA), is designed to meet the needs of hospitals and reference laboratories seeking highly automat.
businesswire.com
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senior, unsecur.
businesswire.com
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. The Managing Board and Supervisory Board of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") have res.
seekingalpha.com
Diagnostics now outperform Life Sciences due to academic funding cuts, making Qiagen's defensive profile more attractive in the current market. Qiagen offers stable growth, high profitability, and low leverage, providing a resilient investment option amid sector volatility and macroeconomic uncertainty. While Qiagen is a strong short-term buy, investors should also consider peers like SysMex, BioMerieux, and CellaVision for diversification and growth potential.
seekingalpha.com
Qiagen N.V. (NYSE:QGEN ) Q2 2025 Earnings Conference Call August 6, 2025 9:30 AM ET Company Participants John Gilardi - Vice President of Corporate Communications & Investor Relations Roland Sackers - CFO, MD & Member of Management Board Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Aisyah Noor - Morgan Stanley, Research Division Casey Rene Woodring - JPMorgan Chase & Co, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Harry MacKinnon Gillis - Joh.
zacks.com
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Qiagen (QGEN) came out with quarterly earnings of $0.6 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.57 per share a year ago.
See all news
